



Genzyme update on supply of Thyrogen® (thyrotropin alfa for injection)

September 12, 2011

Genzyme would like to provide an update on Thyrogen availability. Intermittent shipments of the product have resumed globally with the expectation that current supply projections for the remainder of 2011 will meet approximately 40 to 60 percent of global demand for Thyrogen. Genzyme continues to advise health care providers not to schedule any new Thyrogen treatments until they have secured product.

The manufacturing of Thyrogen and the subsequent process to release the product for shipment are complex processes, and require months to complete. Since Genzyme has extremely limited inventory, even minor changes to our current manufacturing plan impact the timing of Thyrogen availability.

As previously stated, Genzyme continues to expect that Thyrogen supply constraints will occur through 2012. This is due to a combination of factors, including: ongoing Thyrogen manufacturing capacity constraints; longer timelines to manufacture and release Thyrogen into the market; a lack of inventory of the product; and an increase in global demand for Thyrogen. To address this, Genzyme is investing in increasing Thyrogen manufacturing capacity, and working to decrease lot release and production timelines.

Genzyme and Sanofi remain committed to Thyrogen and thyroid cancer patients. We are focused on restoring supply of the product and will continue to provide updates going forward. We sincerely regret the impact the supply constraints have had on the thyroid cancer community.